Thomas Steffi, Kesarwani Vartika, Graber Melanie, Joshi Weishali
Department of Rheumatology, University of Connecticut, Farmington, USA.
Department of Internal Medicine, University of Connecticut, Farmington, USA.
Cureus. 2022 Mar 1;14(3):e22743. doi: 10.7759/cureus.22743. eCollection 2022 Mar.
Adult-onset Still's disease (AOSD) is a rare autoinflammatory disease that typically presents with a triad of fever, evanescent rash, and arthritis. There is often a delay in diagnosis of AOSD due to its nonspecific clinical presentation, which may mimic other infectious, rheumatological disorders, and malignancies. Corticosteroids have been the cornerstone for the management of AOSD for the past many years. However, with the expanding understanding of its pathogenesis, novel therapeutic options targeting various cytokines are being increasingly recognized. Herein, we present a case of AOSD that was successfully treated with tocilizumab, a monoclonal antibody against the interleukin-6 (IL-6) receptor. For the purpose of this article, we also conducted a literature search to review the current therapeutic options available for the treatment of AOSD.
成人斯蒂尔病(AOSD)是一种罕见的自身炎症性疾病,通常表现为发热、一过性皮疹和关节炎三联征。由于其临床表现不具特异性,可能类似其他感染性、风湿性疾病及恶性肿瘤,AOSD的诊断常常延迟。在过去许多年里,糖皮质激素一直是AOSD治疗的基石。然而,随着对其发病机制认识的不断深入,针对各种细胞因子的新型治疗方案越来越受到认可。在此,我们报告一例成功使用托珠单抗(一种抗白细胞介素-6(IL-6)受体的单克隆抗体)治疗的AOSD病例。为撰写本文,我们还进行了文献检索,以回顾目前可用于治疗AOSD的治疗方案。